Elicio Therapeutics (ELTX) Invested Capital (2021 - 2022)

Elicio Therapeutics' (ELTX) quarterly Invested Capital came in at $265000.0 in Q2 2022, down 5.02% on a QoQ basis from $279000.0 in Q1 2022.

Elicio Therapeutics (ELTX) Invested Capital (2021 - 2022) Analysis & Trends

Elicio Therapeutics (ELTX) has 2 years of Invested Capital data on file, last reported at $265000.0 in Q2 2022.

Quarterly Invested Capital changed N/A year-over-year to $265000.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $265000.0 (down 53.67% YoY) and the FY2021 annual result came in at $293000.0, changed N/A from the prior year.
Invested Capital fell to $265000.0 in Q2 2022, from $279000.0 in the prior quarter.
In the past five years, Invested Capital ranged from a high of $293000.0 in Q4 2021 to a low of $265000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	190.90 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.45 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	380.00 Mn
10	Elicio Therapeutics	58.41 Mn	34.91 Mn	-	-

Download Data